Literature DB >> 24132726

Skeletal manifestations of treatment of breast cancer.

Palak Choksi1, Margaret Williams, Patricia M Clark, Catherine Van Poznak.   

Abstract

Breast cancer and osteoporosis are common diagnoses in women. Breast cancer survival has improved due to earlier detection and improved treatments. As most breast cancers are estrogen receptor positive, treatment is often aimed at altering the hormonal environment. Both pre and postmenopausal women undergoing these therapies are at risk for bone loss. The patient's health care team ought to have an awareness of the potential for breast cancer treatments to accelerate bone loss. Women with early stage breast cancer are treated with curative intent and, therefore, maintaining bone health is important and is part of the survivorship care to ensure an optimal quality of life.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24132726      PMCID: PMC3949606          DOI: 10.1007/s11914-013-0179-7

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  87 in total

Review 1.  Update on medications with adverse skeletal effects.

Authors:  Caroline J Davidge Pitts; Ann E Kearns
Journal:  Mayo Clin Proc       Date:  2011-03-09       Impact factor: 7.616

2.  Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial.

Authors:  Ghada El-Hajj Fuleihan; Mariana Salamoun; Yasser Abou Mourad; Aref Chehal; Ziad Salem; Ziyad Mahfoud; Ali Shamseddine
Journal:  J Clin Endocrinol Metab       Date:  2005-03-15       Impact factor: 5.958

3.  Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer.

Authors:  S M Pierce; A Recht; T I Lingos; A Abner; F Vicini; B Silver; A Herzog; J R Harris
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

4.  Circulating tumour cells in non-metastatic breast cancer: a prospective study.

Authors:  Anthony Lucci; Carolyn S Hall; Ashutosh K Lodhi; Anirban Bhattacharyya; Amber E Anderson; Lianchun Xiao; Isabelle Bedrosian; Henry M Kuerer; Savitri Krishnamurthy
Journal:  Lancet Oncol       Date:  2012-06-06       Impact factor: 41.316

5.  Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome.

Authors:  Gro Wiedswang; Elin Borgen; Rolf Kåresen; Hanne Qvist; Jan Janbu; Gunnar Kvalheim; Jahn M Nesland; Bjørn Naume
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

Review 6.  Cancer-treatment-induced bone loss, part 1.

Authors:  Laura Boehnke Michaud; Susan Goodin
Journal:  Am J Health Syst Pharm       Date:  2006-03-01       Impact factor: 2.637

7.  Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.

Authors:  Susan L Greenspan; Adam Brufsky; Barry C Lembersky; Rajib Bhattacharya; Karen T Vujevich; Subashan Perera; Susan M Sereika; Victor G Vogel
Journal:  J Clin Oncol       Date:  2008-04-21       Impact factor: 44.544

8.  Quality of non-breast cancer health maintenance among elderly breast cancer survivors.

Authors:  Craig C Earle; Harold J Burstein; Eric P Winer; Jane C Weeks
Journal:  J Clin Oncol       Date:  2003-04-15       Impact factor: 44.544

9.  Exercise and lumbar spine bone mineral density in postmenopausal women: a meta-analysis of individual patient data.

Authors:  George A Kelley; Kristi S Kelley; Zung Vu Tran
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2002-09       Impact factor: 6.053

10.  Breast-cancer adjuvant therapy with zoledronic acid.

Authors:  Robert E Coleman; Helen Marshall; David Cameron; David Dodwell; Roger Burkinshaw; Maccon Keane; Miguel Gil; Stephen J Houston; Robert J Grieve; Peter J Barrett-Lee; Diana Ritchie; Julia Pugh; Claire Gaunt; Una Rea; Jennifer Peterson; Claire Davies; Victoria Hiley; Walter Gregory; Richard Bell
Journal:  N Engl J Med       Date:  2011-09-25       Impact factor: 91.245

View more
  3 in total

1.  Previous History of Breast Cancer Increases Rates of Pulmonary Embolism and Costs after Total Knee Arthroplasty: An Evaluation of 185,114 Matched Patients.

Authors:  Samuel Rosas; T David Luo; Alexander H Jinnah; Alejandro Marquez-Lara; Martin W Roche; Cynthia L Emory
Journal:  J Knee Surg       Date:  2018-04-04       Impact factor: 2.757

Review 2.  Cancer survivorship issues: life after treatment and implications for an aging population.

Authors:  Julia H Rowland; Keith M Bellizzi
Journal:  J Clin Oncol       Date:  2014-07-28       Impact factor: 44.544

3.  The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial.

Authors:  Peyman Hadji; Oliver Stoetzer; Thomas Decker; Christian M Kurbacher; Frederik Marmé; Andreas Schneeweiss; Christoph Mundhenke; Andrea Distelrath; Peter A Fasching; Michael P Lux; Diana Lüftner; Wolfgang Janni; Mathias Muth; Julia Kreuzeder; Claudia Quiering; Eva-Marie Grischke; Hans Tesch
Journal:  J Bone Oncol       Date:  2018-10-02       Impact factor: 4.072

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.